Supportive of a potential application of HGF in the CF setting, several in vivo studies indicated that HGF administration can mitigate the effects of acute and chronic lung injuries (Panganiban and Day, 2011), having beneficial effects both at the initial and late stages of lung disease (Yaekashiwa et al., 1997; Panganiban and Day, 2011). Here, HGF is linked to lung disorder.